• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Idenix Pharmaceuticals

Idenix Pharmaceuticals

  1. Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver ...

    Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.